UB Paderborn / Katalog / Suche / in CDI

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

Drugs in R&D, 2015-09, Vol.15 (3), p.271-279

2015

Volltextzugriff (PDF)

eP195: Safety and efficacy of Copper Histidinate (CUTX-101) treatment for Menkes disease caused by severe loss-of-function variants in ATP7A

Genetics in medicine, 2022-03, Vol.24 (3), p.S121-S121

2022

Volltextzugriff (PDF)

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD

Journal of the American Society of Nephrology, 2015-10, Vol.26 (10), p.2578-2587

2015

Volltextzugriff (PDF)

Abstract 785: IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B cell lymphomas

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.785-785

2015

Volltextzugriff (PDF)

Abstract 2078: CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2078-2078

2017

Volltextzugriff (PDF)

FERRIC CITRATE: AN IRON-BASED ORAL PHOSPHATE BINDER

Kidney research and clinical practice, 2012-06, Vol.31 (2), p.A38-A39

2012

Volltextzugriff (PDF)

The Role of Sulodexide in the Treatment of Diabetic Nephropathy

Drugs (New York, N.Y.), 2007, Vol.67 (18), p.2681-2696

2007

Volltextzugriff (PDF)

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease

The American journal of gastroenterology, 2000-11, Vol.95 (11), p.3081-3088

2000

Volltextzugriff (PDF)

TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3Kδ Kinase

Blood, 2012-11, Vol.120 (21), p.2610-2610

2012

Volltextzugriff (PDF)

2399 An early phase open-label trial of a novel TARP inhibitor

BMJ neurology open, 2022-08, Vol.4 (Suppl 1), p.A54-A54

2022

Volltextzugriff (PDF)

FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD)

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii270-iii270

2015

Volltextzugriff (PDF)

SP657GASTROINTESTINAL SAFETY AND TOLERABILITY OF FERRIC CITRATE IN PATIENTS WITH ESRD ON DIALYSIS: A POOLED ANALYSIS

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii595-iii595

2015

Volltextzugriff (PDF)

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

Expert review of pharmacoeconomics & outcomes research, 2015-06, Vol.15 (3), p.545-550

2015

Volltextzugriff (PDF)

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis

Clinical nephrology, 2017-03, Vol.87 (2017) (3), p.124

2017

Volltextzugriff (PDF)

Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers

Biopharmaceutics & drug disposition, 2002-05, Vol.23 (4), p.143-149

2002

Volltextzugriff (PDF)

Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data

Expert review of clinical pharmacology, 2014-11, Vol.7 (6), p.705-710

2014

Volltextzugriff (PDF)

Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

Hemodialysis international, 2013-01, Vol.17 (1), p.67-74

2013

Volltextzugriff (PDF)

210: Long-Term Use of Ferric Citrate in ESRD Patients

American journal of kidney diseases, 2010, Vol.55 (4), p.B84-B84

2010

Volltextzugriff (PDF)

Ferric citrate: a novel phosphate-binding agent

Expert review of endocrinology & metabolism, 2013-01, Vol.8 (1), p.13-19

2013

Volltextzugriff (PDF)

Abstract #100: Comparison of Extended-Release Metformin and Immediate-release Metformin

Endocrine practice, 2004-03, Vol.10, p.35

2004

Volltextzugriff (PDF)

Abstract #99: Comparing Efficacy and Tolerability of Metformin XT Given Daily to Immediate-Release Metformin Given Twice Daily in Patients with Type 2 Diabetes

Endocrine practice, 2004-03, Vol.10, p.34-35

2004

Volltextzugriff (PDF)

Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers

Biopharmaceutics & drug disposition, 2004-09, Vol.25 (6), p.261-263

2004

Volltextzugriff (PDF)

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease

The American journal of gastroenterology, 2000, Vol.95 (11), p.3081-3088

2000

Volltextzugriff (PDF)

A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin

Clinical therapeutics, 2002, Vol.24 (1), p.112-125

2002

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

eP195: Safety and efficacy of Copper Histidinate (CUTX-101) treatment for Menkes disease caused by severe loss-of-function variants in ATP7A

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD

Abstract 785: IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B cell lymphomas

Abstract 2078: CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

FERRIC CITRATE: AN IRON-BASED ORAL PHOSPHATE BINDER

The Role of Sulodexide in the Treatment of Diabetic Nephropathy

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease

TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3Kδ Kinase

2399 An early phase open-label trial of a novel TARP inhibitor

FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD)

SP657GASTROINTESTINAL SAFETY AND TOLERABILITY OF FERRIC CITRATE IN PATIENTS WITH ESRD ON DIALYSIS: A POOLED ANALYSIS

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis

Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers

Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data

Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

210: Long-Term Use of Ferric Citrate in ESRD Patients

Ferric citrate: a novel phosphate-binding agent

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Abstract #100: Comparison of Extended-Release Metformin and Immediate-release Metformin

Abstract #99: Comparing Efficacy and Tolerability of Metformin XT Given Daily to Immediate-Release Metformin Given Twice Daily in Patients with Type 2 Diabetes

Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease

A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin

Suchergebnisse filtern